Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20374413 | 0.89 | PDGFRB (0.54) | PDGFRBPDGFRASIRT2MAPTMEN1 | |
| SCHEMBL20362094 | 0.83 | PDGFRB (0.48) | PDGFRBPDGFRAMAPTMEN1KMT2A | |
| SCHEMBL4538765 | 0.80 | MAOB (0.61) | PDGFRBPDGFRASIRT2MAPTMEN1 | |
| SCHEMBL26092553 | 0.74 | MAPT (0.49) | MAPTMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL20362091 | 0.74 | RAB9A (0.64) | PDGFRBPDGFRAMAPTMEN1KMT2A | |
| SCHEMBL28816317 | 0.73 | HTT (0.68) | SIRT2MAPTMEN1KMT2ALMNA | |
| SCHEMBL7195236 | 0.72 | ACHE (0.51) | MAPTMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL8500962 | 0.72 | PDGFRB (0.62) | PDGFRBPDGFRAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10465995 | 0.71 | MAOB (0.65) | PDGFRBPDGFRAMAPTMEN1KMT2A | |
| SCHEMBL8502397 | 0.71 | PDGFRB (1.00) | PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3565807-B1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3565807-B1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3565807-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | Icahn School of Medicine at Mount Sinai (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2018129274-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018129274-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | HIPK2, HIPK3, HIPK1 | PDGFRB 883/4885PDGFRA 1704/4885SIRT2 672/4885 |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | HIPK2, HIPK3, HIPK1 | PDGFRB 883/4885PDGFRA 1704/4885SIRT2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.